CONDENSED COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 52,845	$ 46,973	$ 300,028	$ 139,668
General and administrative	14,792	8,519	54,492	28,349
Total operating expenses	67,637	55,492	354,520	168,017
Loss from operations	(67,637)	(55,492)	(354,520)	(168,017)
Other income (expense):
Gain from equity method investment	0	0	0	5,261
Other expense, net	0	(5)	(71)	(245)
Total other (expense) income, net	0	(5)	(71)	5,016
Loss before provision (benefit) for income taxes	(67,637)	(55,497)	(354,591)	(163,001)
Provision (benefit) for income taxes	1,216	(1,132)	14,581	(1,091)
Net loss and comprehensive loss attributable to common shareholders of Biohaven Ltd.	(68,853)	(54,365)	(369,172)	(161,910)
Net loss and comprehensive loss attributable to common shareholders of Biohaven Ltd.	$ (68,853)	$ (54,365)	$ (369,172)	$ (161,910)
Net loss per share attributable to common shareholders of Biohaven Ltd. — diluted (in dollars per share)	$ (1.75)	$ (1.38)	$ (9.38)	$ (4.11)
Net loss per share attributable to common shareholders of Biohaven Ltd. — basic (in dollars per share)	$ (1.75)	$ (1.38)	$ (9.38)	$ (4.11)
Common shares outstanding—basic (shares)	39,368,042	39,368,042	39,368,042	39,368,042
Common shares outstanding—diluted (shares)	39,368,042	39,368,042	39,368,042	39,368,042